Clinical Trial Update: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating mezigdomide (CC-92480) in relapsed multiple myeloma patients who have previously received idecabtagene vicleucel (ide-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Mezigdomide (mezigdomide)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING